Lithium aluminium hydride, pharmaceutical grade, is a microcrystalline grey powder supplied against assay, residual solvent, and elemental impurity specifications; it is not a compendial excipient and does not survive into finished tablet, capsule, granule, or injectable dosage forms. In bulk active pharmaceutical ingredient manufacture it functions as a strong hydride donor under anhydrous conditions, and the reagent is destroyed during aqueous work-up. The downstream dosage forms that depend on lithium aluminium hydride-mediated reductions include corticosteroid oral solids and injectables, HIV protease inhibitor tablets and oral combinations, prostaglandin analogue tablets, and venlafaxine extended-release capsules. Pharmaceutical-grade material is controlled under ICH Q7 and ICH Q11; typical release data include assay by gas volumetry, particle size distribution by laser diffraction, residual tetrahydrofuran by headspace GC, and lithium/aluminium content by ICP-MS. Process windows referenced in this section are route-dependent; published data for a specific API route may be limited, and site-specific development data are required for batch release.

What Limits the LAH Charge in Corticosteroid C-11 Reductions Destined for Injectable Suspensions?

In corticosteroid routes leading to dexamethasone sodium phosphate injection, betamethasone sodium phosphate injection, and prednisolone tablets, the C-11 ketone intermediate is reduced to the corresponding 11β-alcohol with lithium aluminium hydride in tetrahydrofuran. The reaction mass is maintained between 0°C and 5°C because the competing reduction of the C-20 ketone produces the 17α,20β,21-triol impurity, which is carried into downstream phosphorylation and crystallization if not controlled. A jacketed glass-lined reactor is charged with lithium aluminium hydride as a 10–15% w/w slurry in tetrahydrofuran; substrate is added over 60–120 minutes. The molar ratio of lithium aluminium hydride to C-11 keto intermediate is kept in the range 1.0:1 to 1.2:1. After substrate addition the batch is held for not more than 90 minutes before quench with ethyl acetate and then saturated sodium potassium tartrate. The aluminium alkoxide precipitate is removed through a Nutsche filter equipped with a PTFE cloth; the tetrahydrofuran layer is concentrated under reduced pressure at ≤35°C and the crude alcohol is crystallized from isopropanol/water. Process samples are checked by HPLC using a C18 column and 254 nm detection; the target C-11 alcohol is isolated at ≥98.5% area, with the C-20 reduced impurity at ≤0.15% area. For injectable dexamethasone sodium phosphate, the reduced steroid is phosphorylated and converted to the sodium salt; the parenteral drug product is filled as a sterile solution through a 0.22 µm membrane or lyophilized. Residual lithium is determined by ICP-MS and controlled using a process alert limit derived from the ICH Q3D parenteral lithium PDE of 370 µg/day. Aluminium is not assigned a PDE in ICH Q3D and is therefore controlled by supplier-lot assay and work-up monitoring. Tablet and granule formulations of prednisolone use the same LAH-derived steroid after micronization; wet granulation with lactose monohydrate and povidone is performed at ≤50°C, and granule moisture is maintained below 2.0% w/w before compression. Production-scale failure modes include delayed phase separation when aluminium tartrate forms a gelatinous layer on the filter cloth; a body feed of diatomaceous earth is used to maintain filtration rate.

In HIV protease inhibitor routes, the hydroxyethylamine isostere is assembled by reducing an N-protected α-chloroketone derived from L-phenylalanine to the corresponding amino alcohol with pharmaceutical-grade lithium aluminium hydride. The reduction is run in tetrahydrofuran at −10°C to 0°C to favour the threo amino alcohol; the resulting intermediate is then converted to the hydroxyethylamine core used in ritonavir, lopinavir, and related oral tablet combinations. Ritonavir tablets are manufactured by melt extrusion with copovidone and sorbitan monolaurate; the LAH-derived hydroxyethylamine core is not present in the final dosage form, but its diastereomeric purity controls the crystallization behavior of ritonavir free base and the dissolution profile of the finished tablet. Chiral HPLC with a polysaccharide stationary phase is used to monitor the diastereomeric ratio; the undesired erythro isomer is controlled at ≤0.10% area. Residual tetrahydrofuran and dichloromethane are removed from the isolated intermediate by vacuum drying at ≤40°C and confirmed by headspace GC under USP <467>. Lithium and aluminium are washed out during aqueous sodium tartrate work-up; the final API is tested by ICP-MS for lithium using the ICH Q3D oral PDE of 550 µg/day as the basis for the specification. For oral solid dosage forms, the final drug product is co-processed with microcrystalline cellulose and crospovidone before tablet compression or capsule filling; packaging is selected to limit moisture ingress because the hydroxyethylamine core is hydrolytically sensitive. The reduction vessel is inerted with nitrogen, and hydrogen off-gas from the quench is diluted below 25% of the lower explosive limit for hydrogen, which is 4% v/v.

When a Prostaglandin Lactol Intermediate Must Survive Wittig Olefination Without Ring Opening

Misoprostol and related prostaglandin E1 analogue tablet APIs are prepared from a Corey lactone intermediate that is reduced with lithium aluminium hydride to the corresponding lactol. The reduction is run in tetrahydrofuran at −5°C to 5°C using a hydride-to-lactone molar ratio of 1.0:1 to 1.1:1 because excess hydride can open the lactol ring to a triol impurity. The lactol is isolated as a mixture of anomers and used directly in the Wittig olefination with a phosphonium salt to install the (E)-ω-chain. The final API is misoprostol, which is formulated as tablets with hydroxypropyl methylcellulose for oral administration. The LAH-derived lactol intermediate is not stable under aqueous acidic quench; the work-up uses sodium potassium tartrate and is maintained at pH 7–8. Residual lithium in the isolated intermediate is controlled by ICP-MS to avoid lithium soap formation during Wittig coupling. The final misoprostol tablets are packaged in aluminium/aluminium blisters with a desiccant to control degradation to prostaglandin A compounds; degradation products are monitored by HPLC under USP <621> with a C18 column and phosphate buffer–acetonitrile mobile phase. Tablet content uniformity is tested per USP <905>; the lactol anomer ratio from the LAH step influences the diastereomeric purity of the final prostaglandin. On scale, the quench vessel is equipped with a hydrogen flow meter and flame arrestor; the headspace is nitrogen-purged because residual hydride decomposition can produce a flammable atmosphere. The isolated lactol is not dried above 30°C, and its residual solvent profile is verified against ICH Q3C limits before use in the Wittig step.

In venlafaxine hydrochloride extended-release capsule manufacture, a cyclohexylacetonitrile intermediate is reduced to the corresponding primary amine with pharmaceutical-grade lithium aluminium hydride in refluxing tetrahydrofuran. The nitrile reduction proceeds through an imine intermediate; because the imine is more reactive than the starting nitrile, the hydride charge is controlled and the reactor is kept anhydrous to avoid dimer formation. After the reduction is complete, the batch is quenched using the Fieser work-up: water, 15% w/v aqueous sodium hydroxide, and then water in a 1:1:3 volume ratio per gram of lithium aluminium hydride. The resulting aluminium salts are filtered, the amine is extracted into toluene, and the venlafaxine free base is converted to the hydrochloride salt. Residual nitrile in the venlafaxine free base is measured by GC-MS and controlled at not more than 0.10% area. The final API is coated onto sugar spheres to form sustained-release beads or blended into granules for extended-release capsule filling; dissolution testing is performed in accordance with USP <711> using a paddle apparatus at 50 rpm in 0.1 N hydrochloric acid. Lithium is controlled by ICP-MS in the API because the oral lithium PDE in ICH Q3D is 550 µg/day; for a 225 mg extended-release dose the lithium acceptance criterion is calculated from the allowed daily exposure. The reduction is run under nitrogen in a reactor with a condensate trap for hydrogen off-gas, and the tetrahydrofuran is dried to ≤50 ppm water by Karl Fischer before charging. The granulation process for the extended-release beads is operated at low shear to avoid breakage of the coated pellets; bead moisture and coating integrity are tested before capsule filling.

Residual Aluminium Hydride By-Product Removal in Sterile Injectable APIs

For injectable APIs such as dexamethasone sodium phosphate, methylprednisolone sodium succinate, and naltrexone hydrochloride, the final sterile manufacturing train cannot tolerate particulate aluminium salts. The lithium aluminium hydride work-up is therefore designed to produce a filterable sodium potassium tartrate–aluminium complex. In one production-scale arrangement, the reduced reaction mass is transferred into a stirred quench vessel containing saturated sodium potassium tartrate at 0–10°C; the resulting aluminium tartrate complex is held for 30 minutes and then removed through a 0.45 µm filter followed by a 0.22 µm sterilising-grade filter before the API enters the cleanroom. The filtered organic layer is checked for aluminium by ICP-MS or ICP-OES; a process-specific limit is applied because ICH Q3D does not assign a PDE for aluminium. Lithium is also monitored; for parenteral products the ICH Q3D lithium PDE of 370 µg/day is used to derive the acceptance criterion. Terminal sterilization of the filled injection is performed by autoclaving at 121°C for 15 minutes if the API is thermostable; otherwise sterile filtration is used. For lyophilized products, the drying chamber is inerted with nitrogen and the vials are stoppered under vacuum. Tablet and capsule granulations that use LAH-derived APIs are dry-milled to a D90 of 50–100 µm and blended with excipients in a bin blender; the granule water activity is maintained below 0.60 to avoid hydrolysis of moisture-sensitive APIs. Incoming pharmaceutical-grade lithium aluminium hydride is released only after the supplier provides a documented hydrogen evolution assay, residual solvent data, and a lithium/aluminium mass balance; this is consistent with ICH Q7 Section 8.1 raw-material control and Section 12.7 process validation requirements.